Incretin analogs and inhibitors of DPP-4: Which is their role in the primary prevention of cardiovascular diseases?

Patricio López-Jaramillo; Carlos Velandia; Gabriela Castillo; Tatiana Sánchez; Julie Álvarez

doi:10.1016/s0120-5633(13)70072-x

Incretin analogs and inhibitors of DPP-4: Which is their role in the primary prevention of cardiovascular diseases?

Patricio López-Jaramillo
, Carlos Velandia
, Gabriela Castillo
, Tatiana Sánchez
, Julie Álvarez

Research output: Articles / Notes › Article in a non-specialized journal › peer-review

4 Scopus citations

Abstract

Type 2 diabetes mellitus (T2DM) is a highly prevalent disease, which has shown a rapid increase in recent decades, doubling the number of people with this disease. Several epidemiological studies show that 70% of diabetes deaths are caused by cardiovascular events (coronary heart disease and stroke). Recently there has been an expansion in the discovery of drugs for the management of type 2 diabetes. These drugs must demonstrate additional cardiovascular system benefi ts before its introduction in the market. This paper aims to determine the role of new antidiabetic drugs that act on the incretin system and its effects on the primary prevention of cardiovascular events.

Translated title of the contribution	Análogos de incretina e inhibidores de la DPP-4: ¿qué papel desempeñan en la prevención primaria de las enfermedades cardiovasculares?
Original language	English
Pages (from-to)	287-299
Number of pages	13
Journal	Revista Colombiana de Cardiologia
Volume	20
Issue number	5
DOIs	https://doi.org/10.1016/s0120-5633(13)70072-x
State	Published - 2013
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cardiovascular disease
Diabetes
Inhibitors
Pharmacology

Access to Document

10.1016/s0120-5633(13)70072-x

Cite this

@article{8881c617150644ec8c5b0db695b4ea30,

title = "Incretin analogs and inhibitors of DPP-4: Which is their role in the primary prevention of cardiovascular diseases?",

abstract = "Type 2 diabetes mellitus (T2DM) is a highly prevalent disease, which has shown a rapid increase in recent decades, doubling the number of people with this disease. Several epidemiological studies show that 70\% of diabetes deaths are caused by cardiovascular events (coronary heart disease and stroke). Recently there has been an expansion in the discovery of drugs for the management of type 2 diabetes. These drugs must demonstrate additional cardiovascular system benefi ts before its introduction in the market. This paper aims to determine the role of new antidiabetic drugs that act on the incretin system and its effects on the primary prevention of cardiovascular events.",

keywords = "Cardiovascular disease, Diabetes, Inhibitors, Pharmacology",

author = "Patricio L{\'o}pez-Jaramillo and Carlos Velandia and Gabriela Castillo and Tatiana S{\'a}nchez and Julie {\'A}lvarez",

year = "2013",

doi = "10.1016/s0120-5633(13)70072-x",

language = "Ingl{\'e}s",

volume = "20",

pages = "287--299",

journal = "Revista Colombiana de Cardiologia",

issn = "0120-5633",

publisher = "Permanyer Publications",

number = "5",

}

TY - JOUR

T1 - Incretin analogs and inhibitors of DPP-4

T2 - Which is their role in the primary prevention of cardiovascular diseases?

AU - López-Jaramillo, Patricio

AU - Velandia, Carlos

AU - Castillo, Gabriela

AU - Sánchez, Tatiana

AU - Álvarez, Julie

PY - 2013

Y1 - 2013

N2 - Type 2 diabetes mellitus (T2DM) is a highly prevalent disease, which has shown a rapid increase in recent decades, doubling the number of people with this disease. Several epidemiological studies show that 70% of diabetes deaths are caused by cardiovascular events (coronary heart disease and stroke). Recently there has been an expansion in the discovery of drugs for the management of type 2 diabetes. These drugs must demonstrate additional cardiovascular system benefi ts before its introduction in the market. This paper aims to determine the role of new antidiabetic drugs that act on the incretin system and its effects on the primary prevention of cardiovascular events.

AB - Type 2 diabetes mellitus (T2DM) is a highly prevalent disease, which has shown a rapid increase in recent decades, doubling the number of people with this disease. Several epidemiological studies show that 70% of diabetes deaths are caused by cardiovascular events (coronary heart disease and stroke). Recently there has been an expansion in the discovery of drugs for the management of type 2 diabetes. These drugs must demonstrate additional cardiovascular system benefi ts before its introduction in the market. This paper aims to determine the role of new antidiabetic drugs that act on the incretin system and its effects on the primary prevention of cardiovascular events.

KW - Cardiovascular disease

KW - Diabetes

KW - Inhibitors

KW - Pharmacology

UR - https://www.scopus.com/pages/publications/84896738406

U2 - 10.1016/s0120-5633(13)70072-x

DO - 10.1016/s0120-5633(13)70072-x

M3 - Articulo en revista no especializada

AN - SCOPUS:84896738406

SN - 0120-5633

VL - 20

SP - 287

EP - 299

JO - Revista Colombiana de Cardiologia

JF - Revista Colombiana de Cardiologia

IS - 5

ER -

Incretin analogs and inhibitors of DPP-4: Which is their role in the primary prevention of cardiovascular diseases?

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this